NasdaqGS:NTRABiotechs
Natera Launches Zenith Genomics To Expand Rare Disease Testing Story
Natera (NasdaqGS:NTRA) has launched Zenith Genomics, a next generation whole genome sequencing assay for rare disease detection.
The assay is being introduced in partnership with MyOme, with exclusive collaboration around genome wide rare disease diagnostics.
Zenith Genomics integrates advanced methylation analysis with DNA sequencing to address difficult diagnostic questions in rare conditions.
The launch and supporting data are being presented at a leading medical genetics conference,...